Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity

Andrea Ries Thurman, Thomas Kimble, Betsy Herold, Pedro M M Mesquita, Raina N. Fichorova, Hassan Y. Dawood, Titilayo Fashemi, Neelima Chandra, Lorna Rabe, Tina D. Cunningham, Sharon Anderson, Jill Schwartz, Gustavo Doncel

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Bacterial vaginosis (BV) has been linked to an increased risk of human immunodeficiency virus (HIV) acquisition and transmission in observational studies, but the underlying biological mechanisms are unknown. We measured biomarkers of subclinical vaginal inflammation, endogenous antimicrobial activity, and vaginal flora in women with BV and repeated sampling 1 week and 1 month after completion of metronidazole therapy. We also compared this cohort of women with BV to a healthy control cohort without BV. A longitudinal, open label study of 33 women with a Nugent score of 4 or higher was conducted. All women had genital swabs, cervicovaginal lavage (CVL) fluid, and cervicovaginal biopsies obtained at enrollment and received 7 days of metronidazole treatment. Repeat sampling was performed approximately 1 week and 1 month after completion of therapy. Participant's baseline samples were compared to a healthy, racially matched control group (n=13) without BV. The CVL from women with resolved BV (Nugent 0-3) had significantly higher anti-HIV activity, secretory leukocyte protease inhibitor (SLPI), and growth-related oncogene alpha (GRO-α) levels and their ectocervical tissues had significantly more CD8 cells in the epithelium. Women with persistent BV after treatment had significantly higher levels of interleukin-1β, tumor necrosis factor alpha (TNF-α), and intercellular adhesion molecule 1 (ICAM-1) in the CVL. At study entry, participants had significantly greater numbers of CCR5+ immune cells and a higher CD4/CD8 ratio in ectocervical tissues prior to metronidazole treatment, compared to a racially matched cohort of women with a Nugent score of 0-3. These data indicate that BV is associated with changes in select soluble immune mediators, an increase in HIV target cells, and a reduction in endogenous antimicrobial activity, which may contribute to the increased risk of HIV acquisition.

Original languageEnglish (US)
Pages (from-to)1139-1152
Number of pages14
JournalAIDS Research and Human Retroviruses
Volume31
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Bacterial Vaginosis
Mucosal Immunity
Inflammation
Therapeutic Irrigation
Metronidazole
HIV
Secretory Leukocyte Peptidase Inhibitor
Therapeutics
CD4-CD8 Ratio
Intercellular Adhesion Molecule-1
Interleukin-1
Oncogenes
Observational Studies
Research Design
Epithelium
Tumor Necrosis Factor-alpha
Biomarkers
Biopsy
Control Groups

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Thurman, A. R., Kimble, T., Herold, B., Mesquita, P. M. M., Fichorova, R. N., Dawood, H. Y., ... Doncel, G. (2015). Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. AIDS Research and Human Retroviruses, 31(11), 1139-1152. https://doi.org/10.1089/aid.2015.0006

Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. / Thurman, Andrea Ries; Kimble, Thomas; Herold, Betsy; Mesquita, Pedro M M; Fichorova, Raina N.; Dawood, Hassan Y.; Fashemi, Titilayo; Chandra, Neelima; Rabe, Lorna; Cunningham, Tina D.; Anderson, Sharon; Schwartz, Jill; Doncel, Gustavo.

In: AIDS Research and Human Retroviruses, Vol. 31, No. 11, 01.11.2015, p. 1139-1152.

Research output: Contribution to journalArticle

Thurman, AR, Kimble, T, Herold, B, Mesquita, PMM, Fichorova, RN, Dawood, HY, Fashemi, T, Chandra, N, Rabe, L, Cunningham, TD, Anderson, S, Schwartz, J & Doncel, G 2015, 'Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity', AIDS Research and Human Retroviruses, vol. 31, no. 11, pp. 1139-1152. https://doi.org/10.1089/aid.2015.0006
Thurman, Andrea Ries ; Kimble, Thomas ; Herold, Betsy ; Mesquita, Pedro M M ; Fichorova, Raina N. ; Dawood, Hassan Y. ; Fashemi, Titilayo ; Chandra, Neelima ; Rabe, Lorna ; Cunningham, Tina D. ; Anderson, Sharon ; Schwartz, Jill ; Doncel, Gustavo. / Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. In: AIDS Research and Human Retroviruses. 2015 ; Vol. 31, No. 11. pp. 1139-1152.
@article{1888497c2eb049b29f1d06e5528f2da7,
title = "Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity",
abstract = "Bacterial vaginosis (BV) has been linked to an increased risk of human immunodeficiency virus (HIV) acquisition and transmission in observational studies, but the underlying biological mechanisms are unknown. We measured biomarkers of subclinical vaginal inflammation, endogenous antimicrobial activity, and vaginal flora in women with BV and repeated sampling 1 week and 1 month after completion of metronidazole therapy. We also compared this cohort of women with BV to a healthy control cohort without BV. A longitudinal, open label study of 33 women with a Nugent score of 4 or higher was conducted. All women had genital swabs, cervicovaginal lavage (CVL) fluid, and cervicovaginal biopsies obtained at enrollment and received 7 days of metronidazole treatment. Repeat sampling was performed approximately 1 week and 1 month after completion of therapy. Participant's baseline samples were compared to a healthy, racially matched control group (n=13) without BV. The CVL from women with resolved BV (Nugent 0-3) had significantly higher anti-HIV activity, secretory leukocyte protease inhibitor (SLPI), and growth-related oncogene alpha (GRO-α) levels and their ectocervical tissues had significantly more CD8 cells in the epithelium. Women with persistent BV after treatment had significantly higher levels of interleukin-1β, tumor necrosis factor alpha (TNF-α), and intercellular adhesion molecule 1 (ICAM-1) in the CVL. At study entry, participants had significantly greater numbers of CCR5+ immune cells and a higher CD4/CD8 ratio in ectocervical tissues prior to metronidazole treatment, compared to a racially matched cohort of women with a Nugent score of 0-3. These data indicate that BV is associated with changes in select soluble immune mediators, an increase in HIV target cells, and a reduction in endogenous antimicrobial activity, which may contribute to the increased risk of HIV acquisition.",
author = "Thurman, {Andrea Ries} and Thomas Kimble and Betsy Herold and Mesquita, {Pedro M M} and Fichorova, {Raina N.} and Dawood, {Hassan Y.} and Titilayo Fashemi and Neelima Chandra and Lorna Rabe and Cunningham, {Tina D.} and Sharon Anderson and Jill Schwartz and Gustavo Doncel",
year = "2015",
month = "11",
day = "1",
doi = "10.1089/aid.2015.0006",
language = "English (US)",
volume = "31",
pages = "1139--1152",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity

AU - Thurman, Andrea Ries

AU - Kimble, Thomas

AU - Herold, Betsy

AU - Mesquita, Pedro M M

AU - Fichorova, Raina N.

AU - Dawood, Hassan Y.

AU - Fashemi, Titilayo

AU - Chandra, Neelima

AU - Rabe, Lorna

AU - Cunningham, Tina D.

AU - Anderson, Sharon

AU - Schwartz, Jill

AU - Doncel, Gustavo

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Bacterial vaginosis (BV) has been linked to an increased risk of human immunodeficiency virus (HIV) acquisition and transmission in observational studies, but the underlying biological mechanisms are unknown. We measured biomarkers of subclinical vaginal inflammation, endogenous antimicrobial activity, and vaginal flora in women with BV and repeated sampling 1 week and 1 month after completion of metronidazole therapy. We also compared this cohort of women with BV to a healthy control cohort without BV. A longitudinal, open label study of 33 women with a Nugent score of 4 or higher was conducted. All women had genital swabs, cervicovaginal lavage (CVL) fluid, and cervicovaginal biopsies obtained at enrollment and received 7 days of metronidazole treatment. Repeat sampling was performed approximately 1 week and 1 month after completion of therapy. Participant's baseline samples were compared to a healthy, racially matched control group (n=13) without BV. The CVL from women with resolved BV (Nugent 0-3) had significantly higher anti-HIV activity, secretory leukocyte protease inhibitor (SLPI), and growth-related oncogene alpha (GRO-α) levels and their ectocervical tissues had significantly more CD8 cells in the epithelium. Women with persistent BV after treatment had significantly higher levels of interleukin-1β, tumor necrosis factor alpha (TNF-α), and intercellular adhesion molecule 1 (ICAM-1) in the CVL. At study entry, participants had significantly greater numbers of CCR5+ immune cells and a higher CD4/CD8 ratio in ectocervical tissues prior to metronidazole treatment, compared to a racially matched cohort of women with a Nugent score of 0-3. These data indicate that BV is associated with changes in select soluble immune mediators, an increase in HIV target cells, and a reduction in endogenous antimicrobial activity, which may contribute to the increased risk of HIV acquisition.

AB - Bacterial vaginosis (BV) has been linked to an increased risk of human immunodeficiency virus (HIV) acquisition and transmission in observational studies, but the underlying biological mechanisms are unknown. We measured biomarkers of subclinical vaginal inflammation, endogenous antimicrobial activity, and vaginal flora in women with BV and repeated sampling 1 week and 1 month after completion of metronidazole therapy. We also compared this cohort of women with BV to a healthy control cohort without BV. A longitudinal, open label study of 33 women with a Nugent score of 4 or higher was conducted. All women had genital swabs, cervicovaginal lavage (CVL) fluid, and cervicovaginal biopsies obtained at enrollment and received 7 days of metronidazole treatment. Repeat sampling was performed approximately 1 week and 1 month after completion of therapy. Participant's baseline samples were compared to a healthy, racially matched control group (n=13) without BV. The CVL from women with resolved BV (Nugent 0-3) had significantly higher anti-HIV activity, secretory leukocyte protease inhibitor (SLPI), and growth-related oncogene alpha (GRO-α) levels and their ectocervical tissues had significantly more CD8 cells in the epithelium. Women with persistent BV after treatment had significantly higher levels of interleukin-1β, tumor necrosis factor alpha (TNF-α), and intercellular adhesion molecule 1 (ICAM-1) in the CVL. At study entry, participants had significantly greater numbers of CCR5+ immune cells and a higher CD4/CD8 ratio in ectocervical tissues prior to metronidazole treatment, compared to a racially matched cohort of women with a Nugent score of 0-3. These data indicate that BV is associated with changes in select soluble immune mediators, an increase in HIV target cells, and a reduction in endogenous antimicrobial activity, which may contribute to the increased risk of HIV acquisition.

UR - http://www.scopus.com/inward/record.url?scp=84946724560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946724560&partnerID=8YFLogxK

U2 - 10.1089/aid.2015.0006

DO - 10.1089/aid.2015.0006

M3 - Article

C2 - 26204200

AN - SCOPUS:84946724560

VL - 31

SP - 1139

EP - 1152

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 11

ER -